<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02362893</url>
  </required_header>
  <id_info>
    <org_study_id>2015/159</org_study_id>
    <nct_id>NCT02362893</nct_id>
  </id_info>
  <brief_title>Treatment of Hypertension: an Interventional Approach to Improve Blood Pressure Control</brief_title>
  <acronym>DRIVE</acronym>
  <official_title>Treatment of Hypertension: an Interventional Approach to Improve Blood Pressure Control</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to access the change in mean daytime systolic blood pressure in
      participants with essential hypertension not adequately controlled (defined as mean systolic
      daytime ambulatory blood pressure ≥ 135 mmHg) and randomly assigned to either an intervention
      group with one-time only Direct Observed Therapy (DOT) immediately followed by ABPM or a
      control group with standard ABPM.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      More than 1 billion people world wide suffer from hypertension (HT), leaving it the world´s
      top rank risk factor and contributor to global disease burden. Cardiac disease, stroke,
      kidney disease and dementia are diseases related to HT with high economic burden on societies
      and each year 9.4 million people die as a direct consequence of HT.

      Estimated &lt; 50 % of hypertensive patients adhere to preventive hypertensive medication after
      1 year of treatment.

      Poor adherence to antihypertensive treatment have by many been explained partly by the silent
      nature of hypertension, the risk of side effects from antihypertensive medication, treatment
      expenditures and the patient health perspectives.

      In a randomized controlled trial design we plan to enrol 20 subjects, the limited number
      explained by the study being part of the initial planning of a larger scale trial organized
      by the research group, to invistigate the change in ambulatory bloodpressure with or with out
      Direct Observed Theraphy prior to meassurement, as a one-time-only medication adherence
      check.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in 24-hour ambulatory mean systolic daytime blood pressure</measure>
    <time_frame>Measurement at follow-up visit 3 weeks ± 7 days relative to baseline.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in mean office systolic blood pressure</measure>
    <time_frame>Measurement at follow-up visit 3 weeks ± 7 days relative to baseline.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Direct Observed Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Direct Observed Therapy immediately followed by mounting of ambulatory blood pressure device and measurement of ambulatory blood pressure according to ESH 2013 guidelines.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard care</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Direct Observed Therapy</intervention_name>
    <description>Patients allocated to the intervention group take their medication (from original blister packaged) in front of the invistigator who observe the patient swallowing the medication. To secure the principals of Direct Observed Therapy, the patient do not leave the clinic for two hours.</description>
    <arm_group_label>Direct Observed Therapy</arm_group_label>
    <other_name>DOT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years and above

          -  Residing in Oslo/Akershus

          -  Ambulatory Systolic Daytime Blood Pressure ≥ 135 mmHg

          -  ≥ 2 antihypertensive medications

          -  Be able to read and write Norwegian

        Exclusion Criteria:

          -  Critical illness, ongoing treatment

          -  Known atrial fibrillation

          -  Known heart valve stenosis

          -  Myocardial infarction, angina pectoris or stroke the past 6 months

          -  Known severe renal impairment (eGFR &lt; 30 ml/min/1.73 m2)

          -  History of DOT prior to ABPM

          -  Participation in other interventional study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aud Høieggen, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oslo University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aud Høieggen, MD PhD</last_name>
    <email>aud.hoieggen@medisin.uio.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ulla P Hjørnholm, Bachelor</last_name>
    <email>ullhjo@ous-hf.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>0407</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aud Hoieggen, MD PhD</last_name>
      <email>aud.hoieggen@medisin.uio.no</email>
    </contact>
    <contact_backup>
      <last_name>Ulla P. Hjoernholm</last_name>
      <email>ullhjo@ous-hf.no</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <reference>
    <citation>Fadl Elmula FE, Hoffmann P, Fossum E, Brekke M, Gjønnæss E, Hjørnholm U, Kjær VN, Rostrup M, Kjeldsen SE, Os I, Stenehjem AE, Høieggen A. Renal sympathetic denervation in patients with treatment-resistant hypertension after witnessed intake of medication before qualifying ambulatory blood pressure. Hypertension. 2013 Sep;62(3):526-32. doi: 10.1161/HYPERTENSIONAHA.113.01452. Epub 2013 Jul 8.</citation>
    <PMID>23836798</PMID>
  </reference>
  <reference>
    <citation>Fadl Elmula FE, Hoffmann P, Larstorp AC, Fossum E, Brekke M, Kjeldsen SE, Gjønnæss E, Hjørnholm U, Kjaer VN, Rostrup M, Os I, Stenehjem A, Høieggen A. Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment-resistant hypertension. Hypertension. 2014 May;63(5):991-9. doi: 10.1161/HYPERTENSIONAHA.114.03246. Epub 2014 Mar 3.</citation>
    <PMID>24591332</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 9, 2015</study_first_submitted>
  <study_first_submitted_qc>February 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 13, 2015</study_first_posted>
  <last_update_submitted>April 4, 2018</last_update_submitted>
  <last_update_submitted_qc>April 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oslo University Hospital</investigator_affiliation>
    <investigator_full_name>Ulla Hjørnholm</investigator_full_name>
    <investigator_title>RN MSc</investigator_title>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <keyword>Adherence</keyword>
  <keyword>Direct Observed Therapy (DOT)</keyword>
  <keyword>RCT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

